A comparison of every-third-day versus daily low-dose aspirin therapy on serum thromboxane concentrations in healthy men and women

M. Feldman, B. Cryer, K. Rushin, J. Betancourt

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Aspirin's antithrombotic effect is mediated predominately by inhibition of platelet cyclooxygenase- 1, leading to a decline in serum thromboxane A2 concentrations. We performed a placebo-controlled, randomized, double-blind trial to determine whether aspirin could be given at 3-day intervals and still achieve potent serum thromboxane inhibition. One hundred nine healthy men and women with no recent exposure to aspirin and no contraindications to its use participated. Subjects received 325 mg, 81 mg, or 40 mg of plain aspirin every third day, with placebo on other days; 81 mg of aspirin every day; or placebo every day. Serum concentrations of thromboxane B2 (the metabolite of thromboxane A2) were measured at 3-day intervals during a 31-day treatment period, as well as 4, 7, and 14 days after treatment ended. Serum thromboxane B2 concentrations were nearly identical during treatment with 325 mg of aspirin every third day or 81 mg of aspirin per day (86% inhibition [84%, 89%] and 85% inhibition [73%, 96%], respectively). An aspirin dose of 81 mg every third day was nearly as potent (74% inhibition [70%, 79%]), whereas 40 mg of aspirin every third day achieved only 50% inhibition (40%, 60%). Every-third-day low-dose aspirin regimens (325 and 81 mg) deserve comparison with daily low-dose aspirin regimens in controlled clinical trials because the former regimens could prove to have equal efficacy with reduced toxicity.

Original languageEnglish (US)
Pages (from-to)53-57
Number of pages5
JournalClinical and Applied Thrombosis/Hemostasis
Volume7
Issue number1
StatePublished - 2001

Fingerprint

Thromboxanes
Aspirin
Serum
Therapeutics
Thromboxane B2
Thromboxane A2
Placebos
Cyclooxygenase 1
Controlled Clinical Trials
Blood Platelets

Keywords

  • Aspirin
  • Cyclooxygenase
  • Platelets
  • Serum thromboxane

ASJC Scopus subject areas

  • Hematology

Cite this

A comparison of every-third-day versus daily low-dose aspirin therapy on serum thromboxane concentrations in healthy men and women. / Feldman, M.; Cryer, B.; Rushin, K.; Betancourt, J.

In: Clinical and Applied Thrombosis/Hemostasis, Vol. 7, No. 1, 2001, p. 53-57.

Research output: Contribution to journalArticle

@article{52f5348cb7664e18b84f3fd80c4b053d,
title = "A comparison of every-third-day versus daily low-dose aspirin therapy on serum thromboxane concentrations in healthy men and women",
abstract = "Aspirin's antithrombotic effect is mediated predominately by inhibition of platelet cyclooxygenase- 1, leading to a decline in serum thromboxane A2 concentrations. We performed a placebo-controlled, randomized, double-blind trial to determine whether aspirin could be given at 3-day intervals and still achieve potent serum thromboxane inhibition. One hundred nine healthy men and women with no recent exposure to aspirin and no contraindications to its use participated. Subjects received 325 mg, 81 mg, or 40 mg of plain aspirin every third day, with placebo on other days; 81 mg of aspirin every day; or placebo every day. Serum concentrations of thromboxane B2 (the metabolite of thromboxane A2) were measured at 3-day intervals during a 31-day treatment period, as well as 4, 7, and 14 days after treatment ended. Serum thromboxane B2 concentrations were nearly identical during treatment with 325 mg of aspirin every third day or 81 mg of aspirin per day (86{\%} inhibition [84{\%}, 89{\%}] and 85{\%} inhibition [73{\%}, 96{\%}], respectively). An aspirin dose of 81 mg every third day was nearly as potent (74{\%} inhibition [70{\%}, 79{\%}]), whereas 40 mg of aspirin every third day achieved only 50{\%} inhibition (40{\%}, 60{\%}). Every-third-day low-dose aspirin regimens (325 and 81 mg) deserve comparison with daily low-dose aspirin regimens in controlled clinical trials because the former regimens could prove to have equal efficacy with reduced toxicity.",
keywords = "Aspirin, Cyclooxygenase, Platelets, Serum thromboxane",
author = "M. Feldman and B. Cryer and K. Rushin and J. Betancourt",
year = "2001",
language = "English (US)",
volume = "7",
pages = "53--57",
journal = "Clinical and Applied Thrombosis/Hemostasis",
issn = "1076-0296",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - A comparison of every-third-day versus daily low-dose aspirin therapy on serum thromboxane concentrations in healthy men and women

AU - Feldman, M.

AU - Cryer, B.

AU - Rushin, K.

AU - Betancourt, J.

PY - 2001

Y1 - 2001

N2 - Aspirin's antithrombotic effect is mediated predominately by inhibition of platelet cyclooxygenase- 1, leading to a decline in serum thromboxane A2 concentrations. We performed a placebo-controlled, randomized, double-blind trial to determine whether aspirin could be given at 3-day intervals and still achieve potent serum thromboxane inhibition. One hundred nine healthy men and women with no recent exposure to aspirin and no contraindications to its use participated. Subjects received 325 mg, 81 mg, or 40 mg of plain aspirin every third day, with placebo on other days; 81 mg of aspirin every day; or placebo every day. Serum concentrations of thromboxane B2 (the metabolite of thromboxane A2) were measured at 3-day intervals during a 31-day treatment period, as well as 4, 7, and 14 days after treatment ended. Serum thromboxane B2 concentrations were nearly identical during treatment with 325 mg of aspirin every third day or 81 mg of aspirin per day (86% inhibition [84%, 89%] and 85% inhibition [73%, 96%], respectively). An aspirin dose of 81 mg every third day was nearly as potent (74% inhibition [70%, 79%]), whereas 40 mg of aspirin every third day achieved only 50% inhibition (40%, 60%). Every-third-day low-dose aspirin regimens (325 and 81 mg) deserve comparison with daily low-dose aspirin regimens in controlled clinical trials because the former regimens could prove to have equal efficacy with reduced toxicity.

AB - Aspirin's antithrombotic effect is mediated predominately by inhibition of platelet cyclooxygenase- 1, leading to a decline in serum thromboxane A2 concentrations. We performed a placebo-controlled, randomized, double-blind trial to determine whether aspirin could be given at 3-day intervals and still achieve potent serum thromboxane inhibition. One hundred nine healthy men and women with no recent exposure to aspirin and no contraindications to its use participated. Subjects received 325 mg, 81 mg, or 40 mg of plain aspirin every third day, with placebo on other days; 81 mg of aspirin every day; or placebo every day. Serum concentrations of thromboxane B2 (the metabolite of thromboxane A2) were measured at 3-day intervals during a 31-day treatment period, as well as 4, 7, and 14 days after treatment ended. Serum thromboxane B2 concentrations were nearly identical during treatment with 325 mg of aspirin every third day or 81 mg of aspirin per day (86% inhibition [84%, 89%] and 85% inhibition [73%, 96%], respectively). An aspirin dose of 81 mg every third day was nearly as potent (74% inhibition [70%, 79%]), whereas 40 mg of aspirin every third day achieved only 50% inhibition (40%, 60%). Every-third-day low-dose aspirin regimens (325 and 81 mg) deserve comparison with daily low-dose aspirin regimens in controlled clinical trials because the former regimens could prove to have equal efficacy with reduced toxicity.

KW - Aspirin

KW - Cyclooxygenase

KW - Platelets

KW - Serum thromboxane

UR - http://www.scopus.com/inward/record.url?scp=0035144529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035144529&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 53

EP - 57

JO - Clinical and Applied Thrombosis/Hemostasis

JF - Clinical and Applied Thrombosis/Hemostasis

SN - 1076-0296

IS - 1

ER -